[go: up one dir, main page]

MX2023005878A - Metodos para modular las interacciones de la superficie de la celula huesped con sars-cov-2. - Google Patents

Metodos para modular las interacciones de la superficie de la celula huesped con sars-cov-2.

Info

Publication number
MX2023005878A
MX2023005878A MX2023005878A MX2023005878A MX2023005878A MX 2023005878 A MX2023005878 A MX 2023005878A MX 2023005878 A MX2023005878 A MX 2023005878A MX 2023005878 A MX2023005878 A MX 2023005878A MX 2023005878 A MX2023005878 A MX 2023005878A
Authority
MX
Mexico
Prior art keywords
cov
methods
sars
host cell
cell surface
Prior art date
Application number
MX2023005878A
Other languages
English (en)
Inventor
Nadia Martinez-Martin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2023005878A publication Critical patent/MX2023005878A/es

Links

Classifications

    • C07K16/104—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)

Abstract

En la presente se proporcionan métodos para tratar o prevenir la infección por SARS-CoV-2 que comprenden modular las interacciones entre la proteína espicular de SARS-CoV-2 y las proteínas de la célula huésped expresadas en la membrana plasmática, así como métodos para identificar moduladores de tales interacciones.
MX2023005878A 2020-11-23 2021-11-23 Metodos para modular las interacciones de la superficie de la celula huesped con sars-cov-2. MX2023005878A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063117440P 2020-11-23 2020-11-23
PCT/US2021/060464 WO2022109441A1 (en) 2020-11-23 2021-11-23 Methods for modulating host cell surface interactions with sars-cov-2

Publications (1)

Publication Number Publication Date
MX2023005878A true MX2023005878A (es) 2023-06-05

Family

ID=79288106

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005878A MX2023005878A (es) 2020-11-23 2021-11-23 Metodos para modular las interacciones de la superficie de la celula huesped con sars-cov-2.

Country Status (12)

Country Link
US (1) US20240025972A1 (es)
EP (1) EP4247494A1 (es)
JP (1) JP2023554592A (es)
KR (1) KR20230113329A (es)
CN (1) CN117425736A (es)
AU (1) AU2021381455A1 (es)
BR (1) BR112023009875A2 (es)
CA (1) CA3200885A1 (es)
IL (1) IL302935A (es)
MX (1) MX2023005878A (es)
TW (1) TW202237178A (es)
WO (1) WO2022109441A1 (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
JP2001526893A (ja) * 1997-12-23 2001-12-25 イミュネックス・コーポレーション Ｔｉｇｉｒｒｄｎａおよびポリペプチド
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
JP2002533726A (ja) 1998-12-28 2002-10-08 サネシス ファーマシューティカルス インコーポレイテッド 結合のための小有機分子リガンドの同定
AT506258A1 (de) 2007-12-18 2009-07-15 Apeiron Biolog Forschungs Und Behandlung inflammatorischer krankheiten
AU2008365142A1 (en) 2008-12-09 2010-06-17 Sca Hygiene Products Ab Fibrous product with a rastered embossing and method for producing same
EP2625203A1 (en) * 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
KR101780575B1 (ko) * 2013-02-14 2017-09-21 건국대학교 산학협력단 신규한 인터루킨-33 수용체와 결합 단백질 조성물 및 그 용도
AU2014233494B2 (en) 2013-03-15 2018-10-04 Genentech, Inc. IL-22 polypeptides and IL-22 Fc fusion proteins and methods of use
WO2016008051A1 (en) * 2014-07-15 2016-01-21 Mcmaster University Contactin-1 (cntn1) for use in methods of diagnosis and treatment of prostate cancer
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
EP3574094A4 (en) 2017-01-24 2020-11-11 Northwestern University LOW MOLECULAR WEIGHT ACTIVE VARIANTS OF ANGIOTENSIN II CONVERTING ENZYME (ECA II)
WO2018218231A1 (en) * 2017-05-25 2018-11-29 The Broad Institute, Inc. Lymphocyte antigen cd5like (cd5l) monomer, homodimer, and interleukin 12b (p40) heterodimer antagonists and methods of use thereof
CN113874031A (zh) * 2019-03-29 2021-12-31 苏黎士大学 局部递送到区室，特别是CNS的Fc修饰的生物制品
JP7116256B1 (ja) * 2020-04-02 2022-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片
WO2021207858A1 (en) * 2020-04-17 2021-10-21 London Health Sciences Centre Research Inc. Diagnosis and treatment of covid-19

Also Published As

Publication number Publication date
CN117425736A (zh) 2024-01-19
US20240025972A1 (en) 2024-01-25
IL302935A (en) 2023-07-01
AU2021381455A1 (en) 2023-06-29
WO2022109441A1 (en) 2022-05-27
TW202237178A (zh) 2022-10-01
BR112023009875A2 (pt) 2024-02-06
JP2023554592A (ja) 2023-12-28
CA3200885A1 (en) 2022-05-27
KR20230113329A (ko) 2023-07-28
EP4247494A1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
AR122050A2 (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
MX2024006720A (es) Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas
BR112018073861A2 (pt) métodos de terapia de genes para doenças e condições relacionadas com a idade
BR112019012964A2 (pt) polipeptídeos multiméricos moduladores de célula t e métodos de uso dos mesmos
BR112018007538A2 (pt) células exterminadoras naturais e células ilc3 e usos das mesmas
AU2018289493A1 (en) Methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction
BR112016028512A8 (pt) método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante
AU2017241807A1 (en) Medium, methods, cells and secreted factors for stem cell culture and therapy
BR112018070578A2 (pt) composições, sistemas, kits, e métodos para tratar uma infecção
BR112021019365A2 (pt) Métodos para identificar um indivíduo que tem câncer, para selecionar uma terapia, para identificar uma interação proteína-proteína e para identificar um modulador, métodos de tratamento de um indivíduo com câncer, de identificação, de seleção de uma terapia e de identificação de um modulador, coleções de polipeptídeos, de vetores e de células e moduladores isolados
AR121390A1 (es) Composiciones y métodos para tratar la deficiencia auditiva no relacionada con la edad en un sujeto humano
BR112013016935A2 (pt) modulação da dineína na pele
BR112013018229A2 (pt) sistema de remoção de espécies iônicas
MX2021015620A (es) Célula para resistir reacción al trasplante y método.
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
AR080722A2 (es) Metodo para regular la expresion de un blanco con una construccion de nucleotidos y para tratar un acondicion patologica
MX2017008567A (es) Dnasa modificada y usos de la misma.
CL2023003260A1 (es) Composiciones y métodos para el tratamiento de la hipoacusia neurosensorial mediante sistemas de vector dual de estereocilina.
CL2017003309A1 (es) Métodos de purificación y/o inactivación viral
MX2019005693A (es) Factor viii direccionado a los globulos rojos y metodo para su uso.
MX383505B (es) Eliminación de la cistina mediada por enzimas humanas.
MX2022015284A (es) Composiciones y metodos para la edicion del epigenoma.
MX2021010061A (es) Proteínas de fusión fc con dominio extracelular de cd80 para tratar tumores negativos para pd-l1.
MX2023005878A (es) Metodos para modular las interacciones de la superficie de la celula huesped con sars-cov-2.
MX2022001518A (es) Composiciones que comprenden enzimas digestivas.